Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Full text

Free full text

Publication Types

Journal Article

Research Support, Non-U.S. Gov't

Randomized Controlled Trial

Multicenter Study

Review

Research Support, N.I.H., Extramural

Research Support, U.S. Gov't, Non-P.H.S.

Clinical Trial, Phase II

Publication Year

From

Quick links

Individual year

2021

2020

2019

2018

2017

2016

2015

2014

2013

2011

2010

2008

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Phospholipase A2 Inhibitors""[mesh_terms]

18 Results

Searching titles within these results

The design and discovery of phospholipase A inhibitors for the treatment of inflammatory diseases.

Charikleia S Batsika, Anna-Dimitra D Gerogiannopoulou, Christiana Mantzourani, Sofia Vasilakaki, George Kokotos

Expert opinion on drug discovery 2021;16(11):1287-1305

Full Text

Abstract

Therapeutic potential of arachidonyl trifluromethyl ketone, a cytosolic phospholipaseA IVA specific inhibitor, in cigarette smoke condensate-induced pathological conditions in alveolar type I & II epithelial cells.

Subodh Kumar, Sanjeev Kumar Sharma, Gaurav Kaushik, Pramod Kumar Avti, Satish Kumar Pandey, Phulen Sarma, Bikash Medhi, Krishan Lal Khanduja

Toxicology in vitro : an international journal published in association with BIBRA 2019;54():215-223

Full Text

Abstract

Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease.

Ralph A H Stewart, Claes Held, Sue Krug-Gourley, Dawn Waterworth, Amanda Stebbins, Karen Chiswell, Emil Hagstrom, Paul W Armstrong, Lars Wallentin, Harvey White

Journal of the American Heart Association 2020;8(7):e010641

Free Full Text

Abstract

Effects of Phospholipase A2 Inhibitors on Bilayer Lipid Membranes.

Mikhail V Dubinin, Maxim E Astashev, Nikita V Penkov, Sergey V Gudkov, Igor A Dyachenko, Victor N Samartsev, Konstantin N Belosludtsev

The Journal of membrane biology 2017;249(3):339-47

Full Text

Abstract

Computer-aided drug design guided by hydrogen/deuterium exchange mass spectrometry: A powerful combination for the development of potent and selective inhibitors of Group VIA calcium-independent phospholipase A.

Varnavas D Mouchlis, Christophe Morisseau, Bruce D Hammock, Sheng Li, J Andrew McCammon, Edward A Dennis

Bioorganic & medicinal chemistry 2017;24(20):4801-4811

Free Full Text

Abstract

Investigational drugs in sickle cell anemia.

Samir K Ballas, Sandy D Kotiah

Expert opinion on investigational drugs 2010;18(12):1817-28

Full Text

Abstract

Can Inhibitors of Snake Venom Phospholipases A₂ Lead to New Insights into Anti-Inflammatory Therapy in Humans? A Theoretical Study.

Thaís A Sales, Silvana Marcussi, Elaine F F da Cunha, Kamil Kuca, Teodorico C Ramalho

Toxins 2018;9(11):341

Free Full Text

Abstract

Darapladib, a lipoprotein-associated phospholipase A2 inhibitor, in diabetic macular edema: a 3-month placebo-controlled study.

Giovanni Staurenghi, Li Ye, Mindy H Magee, Ronald P Danis, John Wurzelmann, Peter Adamson, Megan M McLaughlin

Ophthalmology 2015;122(5):990-6

Full Text

Abstract

Physical activity in patients with stable coronary heart disease: an international perspective.

Ralph Stewart, Claes Held, Rebekkah Brown, Ola Vedin, Emil Hagstrom, Eva Lonn, Paul Armstrong, Christopher B Granger, Judith Hochman, Richard Davies, Joseph Soffer, Lars Wallentin, Harvey White

European heart journal 2014;34(42):3286-93

Free Full Text

Abstract

Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease.

Daniel Lindholm, Johan Lindbäck, Paul W Armstrong, Andrzej Budaj, Christopher P Cannon, Christopher B Granger, Emil Hagström, Claes Held, Wolfgang Koenig, Ollie Östlund, Ralph A H Stewart, Joseph Soffer, Harvey D White, Robbert J de Winter, Philippe Gabriel Steg, Agneta Siegbahn, Marcus E Kleber, Alexander Dressel, Tanja B Grammer, Winfried März, Lars Wallentin

Journal of the American College of Cardiology 2017;70(7):813-826

Free Full Text

Abstract

Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial.

Preethi Mani, Rishi Puri, Gregory G Schwartz, Steven E Nissen, Mingyuan Shao, John J P Kastelein, Venu Menon, A Michael Lincoff, Stephen J Nicholls

JAMA cardiology 2020;4(4):314-320

Free Full Text

Abstract

The application of rational design on phospholipase A(2) inhibitors.

V D Mouchlis, E Barbayianni, T M Mavromoustakos, G Kokotos

Current medicinal chemistry 2011;18(17):2566-82

Full Text

Abstract

Effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity in Japanese dyslipidemic patients, with exploratory analysis of a PLA2G7 gene polymorphism of Val279Phe.

Hiroyuki Daida, Takayuki Iwase, Shigeru Yagi, Hidekazu Ando, Hiromu Nakajima

Circulation journal : official journal of the Japanese Circulation Society 2013;77(6):1518-25

Free Full Text

Abstract

Therapeutic Role of Innovative Anti-Inflammatory Medications in the Prevention of Acute Coronary Syndrome.

William H Frishman, Raymond Anthony Pashun

Cardiology in review 2016;23(5):252-60

Full Text

Abstract

Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: baseline results from the STABILITY study.

Ola Vedin, Emil Hagström, Ralph Stewart, Rebekkah Brown, Susan Krug-Gourley, Richard Davies, Lars Wallentin, Harvey White, Claes Held

European journal of preventive cardiology 2014;20(4):678-85

Full Text

Abstract

Results: 1 – 15 / 18

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Phospholipase A2 Inhibitors""[mesh_terms]

The design and discovery of phospholipase A inhibitors for the treatment of inflammatory diseases.

Therapeutic potential of arachidonyl trifluromethyl ketone, a cytosolic phospholipaseA IVA specific inhibitor, in cigarette smoke condensate-induced pathological conditions in alveolar type I & II epithelial cells.

Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease.

Effects of Phospholipase A2 Inhibitors on Bilayer Lipid Membranes.

Computer-aided drug design guided by hydrogen/deuterium exchange mass spectrometry: A powerful combination for the development of potent and selective inhibitors of Group VIA calcium-independent phospholipase A.

Investigational drugs in sickle cell anemia.

Can Inhibitors of Snake Venom Phospholipases A₂ Lead to New Insights into Anti-Inflammatory Therapy in Humans? A Theoretical Study.

Darapladib, a lipoprotein-associated phospholipase A2 inhibitor, in diabetic macular edema: a 3-month placebo-controlled study.

Physical activity in patients with stable coronary heart disease: an international perspective.

Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease.

Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial.

The application of rational design on phospholipase A(2) inhibitors.

Effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity in Japanese dyslipidemic patients, with exploratory analysis of a PLA2G7 gene polymorphism of Val279Phe.

Therapeutic Role of Innovative Anti-Inflammatory Medications in the Prevention of Acute Coronary Syndrome.

Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: baseline results from the STABILITY study.

Results for
""Phospholipase A2 Inhibitors""[mesh_terms]